Zydus Lifesciences has informed that it enclosed a copy of press release dated March 3, 2023 titled ‘Zydus receives final approval from the USFDA for Vigabatrin for Oral Solution USP, 500 mg’.
The above information is a part of company’s filings submitted to BSE.